Interview with Dr Dina Coertzen, University of Pretoria, MMV’s African Challenges Grantee 8 August 2023
MMV receives rank of “very high performer” in 2023 Global Health 50/50 report for 2nd year 27 July 2023
Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase 26 July 2023 Res Sq
Malaria eradication impossible without addressing pregnancy treatment and prevention options 11 July 2023
Moving seasonal malaria chemoprevention out of its geographical isolation 3 July 2023 Lancet Infect Dis
MMV awards Dr Stephen Brand-led team for developing innovative dose prediction tool 'MMVSola' 27 June 2023
MMV achievements in 2022 26 June 2023 Throughout 2022, MMV helped treat and protect millions of people against malaria while making significant progress in multiple key areas. See the infographic below for more details.
MMV Annual Report 2022 26 June 2023 Read an in-depth overview of MMV's activities and our financial statements for 2022.
Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial 12 June 2023 Lancet Infect Dis
Brazil becomes the first malaria-endemic country to adopt single-dose tafenoquine and STANDARD G6PD Test for the treatment of relapsing Plasmodium vivax malaria 6 June 2023
Rectal artesunate for severe malaria, implementation research, Zambia 31 May 2023 Bull World Health Organ
